Probiotic and Colchicine in COVID-19

• Status: Completed
• Trial end date: 2022-08-30
• Target enrollment: 0
• Participant gender: All

Summary

Coronavirus disease 2019 (COVID-19) is a newly emerging human disease caused by a novel coronavirus causing a global pandemic crisis.

Currently there is no specific treatment for COVID-19, Probiotics and or Colchicine may be considered as an option of treatment since they have anti-viral effect anti-inflammatory and immunomodulatory effect.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Colchicine

Criteria

Inclusion Criteria:

• Patients aged (18-60) years with confirmed criteria of COVID-19 infection. Mild cases:

Patients have mild symptoms such as anosmia, loss of taste, fever or respiratory tract symptoms, gastrointestinal symptoms, etc. and free chest imaging. Moderate Cases: Patients have symptoms such as fever, respiratory tract symptoms, gastrointestinal symptoms, etc. and pneumonia manifestations can be seen in chest imaging

Exclusion Criteria:

• Age below 18 years or above 60 years.

• Pregnancy, lactation.

• Any co-morbidities e.g. (DM, hypertension, Asthma)

• Patients receiving immunosuppressive or chemotherapy drugs.

• Active malignancy

• Severe confirmed cases, fulfilling any of the following criteria:

1. Respiratory rate more than 30/min.

2. Blood oxygen saturation of less than 93%.

3. Lung infiltrates >50% of the lung fields or rapid progression within 24-48 hours.

4. Patients need respiratory support e.g. high flow oxygen, non-invasive or invasive mechanical ventilation.

• Critical cases defined as: occurrence of respiratory failure requiring mechanical ventilation; Presence of shock; other organ failure that requires monitoring and treatment in the ICU